Recombinant Cynomolgus/Rhesus Macaque CD19 Fc Protein, CF Summary
|Cynomolgus Monkey CD19|
Accession # XP_005591597
Complete Your Research
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
2 μg/lane of Recombinant Cynomolgus Monkey CD19 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing bands at 86-99 kDa and 170-190 kDa, respectively.
CD19 is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 is expressed throughout B cell development from pre-B cells through mature B cells, and it is commonly used as a B cell lineage marker (1). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (4, 5). CD19 associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu13, (6-9). These associations enable CD19 to amplify B cell signaling (7, 9-12) and reduce the threshold for antigen stimulation through the BCR (13). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors. Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has proven effective in many different cancers. The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials. Mature human CD19 consists of a 272 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 22 aa transmembrane segment, and a 243 aa cytoplasmic domain (3). Within the ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19.
- Wang, K. et al. (2012) Exp. Hematol. Oncol. 1:36.
- Tedder, T.F. et al. (1997) Immunity 6:107.
- Tedder, T.F. and C.M. Isaacs (1989) J. Immunol. 143:712.
- Rickert, R.C. et al. (1995) Nature 376:352.
- Engel, P. et al. (1995) Immunity 3:39.
- Vences-Catalan, F. et al. (2012) J. Immunol. 137:48.
- Deaglio, S. et al. (2007) Blood 109:5390.
- Bradbury, L. et al. (1992) J. Immunol. 149:2841.
- Krop, I. et al. (1996) J. Immunol. 157:48.
- O'Rourke, L.M. et al. (1998) Immunity 8:635.
- Buhl, A.M. et al. (1997) J. Exp. Med. 186:1897.
- Sato, S. et al. (1995) Proc. Natl. Acad. Sci. USA 92:11558.
- Carter, R.H. and D.T. Fearon (1992) Science 256:105.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Cynomolgus/Rhesus Macaque CD19 Fc Protein, CF
Average Rating: 5 (Based on 5 Reviews)
Have you used Recombinant Cynomolgus/Rhesus Macaque CD19 Fc Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image